Method for estimating therapeutic efficacy of tumor necrosis factor

Abstract

Disclosed is a method for estimating the therapeutic efficacy of physiologically active substances or antitumor agents, particularly, tumor necrosis factor (TNF-α) in the treatment of cancers. The method comprises a step of evaluating the expression level of a TNF-α-related gene in a cancer cell.

Description

BACKGROUND OF THE INVENTION

[0001] 1. Field of the Invention

[0002] The present invention relates to a method for estimating the potential therapeutic efficacy of physiologically active substances or anti-tumor agents, particularly, tumor necrosis factor (hereinafter abbreviated as “TNF-α” throughout the specification) in the treatment of cancers.

[0003] 2. Description of the Prior Art

[0004] Treatments with antitumor agents have been used in medical fields as effective therapeutic methods for treating cancers. Conventional antitumor agents, however, are only effective on restricted types of cancers, and this narrows their applicability. In addition, there are not so many antitumor agents with satisfactory therapeutic efficacy. Most of conventional antitumor agents have relatively strong side effects, and this results in a heavy burden to cancer patients as a serious demerit.

[0005] Recently, as novel antitumor agents, the use of physiologically active substances have been highlighted. Comparing with conventional antitumor agents mainly produced by chemical synthesis, such physiologically active substances have the merit that they have a relatively wide applicability because of their satisfactory antitumor effects on more various types of cancers. Among the physiologically active substances, particularly, TNF-α, which was discovered by L. J. Old et al. in 1975 as a cytotoxic factor secreted in sera of animals such as rabbits and mice which had been sequentially administered with BCG and intracellular toxin, has been focused on as a physiologically active substance with a strong antitumor activity on a variety of antitumor cells since the discovery. However, even the above TNF-α has serious side effects similarly as in conventional antitumor agents and subsidiary acts on some types of cells to cause fever, and therefore, TNF-α has not yet been actually used in medical fields.

[0006] Due to the genetic progress such as the total human gene analysis as a result of the worldwide project, gene-related screening tools such as DNA microarray technology have been rapidly progressed. Jikken-Igaku, extra number, edited by H. Aburatani, Vol. 19, No. 19, pp. 2,518-2,524 (2001) discloses a trial of applying the analysis of gene expression profiles using DNA microarray technology to accurately evaluate the properties of cancers in diagnosing cancers; and Jikken-Igaku, extra number, edited by K. Chiba et al, Vol. 19, No. 19, pp. 2,507-2,512 (2001) proposes a trial of estimating the individual difference in effects of pharmaceuticals such as antitumor agents, i.e., pharmacogenomics. Since the above trials would directly enable an appropriate selection of a potent therapy without actually conducting therapies with trials and errors in diagnosing and treating diseases such as cancers, it is surely expected that such trials will lower patients' physical burdens and the doses of expensive medicines and effectively reduce patients' economical burdens such as medical costs. Although there are not so many actually applicable cases to which the above methods for estimating efficacy of medicines are applicable, future researches would increase such cases. Although there has not yet been established such methods applicable to antitumor agents including TNF-α, such a method, when established, will possibly be a breakthrough in applying to cancer treatment antitumor agents including TNF-α, which could not have been used in clinical treatments because of their undesirable side effects in spite of their outstanding physiological activities.

SUMMARY OF THE INVENTION

[0007] The present invention aims to provide a method for estimating the therapeutic efficacy of physiologically active substances or anti-tumor agents, particularly, TNF-α in treating cancers.

[0008] To overcome the above object, the present inventors widely screened the expression profiles of genes such as apoptosis-related genes and TNF-α-related genes in established cell lines derived from cancers, found genes which are deeply related to sensitivity to TNF-α; and examined the expression levels of these genes to establish the method for estimating the therapeutic efficacy of TNF-α in cancer treatment. Thus, the present inventors accomplished this invention.

[0009] The present invention estimates the therapeutic efficacy of TNF-α in cancer treatment based on the gene expression of TNF-α-related gene, particularly, a protein kinase B (Akt-1) gene, death receptor (DR3) gene, multidrug resistance-associated protein (MRP5) gene, or multidrug resistance-associated protein (MRP6) gene.

BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWING

[0010] FIG. 1 shows a relative expression level of Akt-1 gene with respect to the mRNA level of TNF-α sensitive cells in each rank.

[0011] FIG. 2 shows a relative expression level of DR3 gene with respect to the mRNA level of TNF-α sensitive cells in each rank.

[0012] FIG. 3 shows a relative expression level of MRP5 gene with respect to the mRNA level of TNF-α sensitive cells in each rank.

[0013] FIG. 4 shows a relative expression level of MRP6 gene with respect to the mRNA level of TNF-α sensitive cells in each rank.

[0014] FIG. 5 is a comparison of the expression level of Akt-1 gene with respect to mRNA level in each type of cells from different origins.

[0015] FIG. 6 is a result of cluster analysis of TNF-α-related gene.

[0016] FIG. 7 shows a relationship between the sensitivity of cells to TNF-α and the expression level of Akt-1 gene or ICAM-1, where the symbols “▾” and “∘” mean TNF-α-sensitive cells and non-TNF-α-sensitive cells, respectively.

DETAILED DESCRIPTION OF THE INVENTION

[0017] The term “TNF-α” as referred to as in the present invention means TNF-α in general obtainable from humans or other warm-blooded animals; those produced by culturing cells of humans or other warm-blooded animals in an appropriate manner, and contacting the cells with appropriate TNF-α inducers to produce TNF-α; those produced by preparing appropriate expression vectors introduced with TNF-α genes of humans or other warm-blooded animals, introducing the expression vectors into microorganisms such as Escherichia coli or yeasts, animal- or plant-bodies, or cultured animal- or plant-cells, and optionally allowing the resulting transformants to express TNF-α using TNF-α inducers; and those which are totally or partially produced by chemical syntheses by the protein engineering. These TNF-α preparations include natural and recombinant TNF-αs independently of their preparation methods and origins, and further include those which are produced in vivo by administering TNF-α inducers to patients or by allowing to express external TNF-α genes introduced into patients' bodies by means of gene therapy. In addition, to control the stability, action and effect of TNF-α, the TNF-αs usable in the present invention include those which are modified with N-glycosylated or O-glycosylated saccharide chains composed of monosaccharides such as glucose, galactose, N-acetyl glucosamine, N-acetyl galactosamine, fucose, mannose, xylose, and sialic acid; those which are modified with saccharide chains composed of saccharides sulfonated with hyaluronic acid or heparan sulfonate; those which are modified with water-soluble high molecules such as polyethylene glycol and poly vinyl alcohol; and those which are partially modified in their amino acid sequences without losing TNF-α activity.

[0018] In the present invention, TNF-α can be used in combination with one or more other substances, for example, physiologically active substances such as interferons, interleukins, and growth hormones; and pharmaceuticals such as antitumor agents, antibiotics, vaccines, crude drugs, and herbal medicines.

[0019] The term “TNF-α-related genes” as referred to as in the present invention means genes which are induced their expression by TNF-α or which are related to the expression of TNF-α induction, for example, TNF-α-receptor genes, apoptosis-related genes, TNF-α-signal-transduction-related genes, multidrug resistance-associated genes, etc., particularly, the genes in Table 3 as described later. Specifically, prokinase B (hereinafter may be abbreviated as “Akt-1” throughout the specification) gene, a TNF-α-signal-related-gene; death receptor 3 (hereinafter may be abbreviated as “DR3” throughout the specification), receptor-related gene; multidrug resistance-associated protein 5 (hereinafter may be abbreviated as “MRP5” throughout the specification); and multidrug resistance-associated protein 6 (hereinafter may be abbreviated as “MRP6” throughout the specification) which are all deeply related to the therapeutic efficacy of TNF-α because cells, in which these genes are expressed in quantity, have a relatively high sensitivity to TNF-α. Thus, the examination of the expression level of these genes will be advantageously, effectively used in estimating the therapeutic efficacy of TNF-α.

[0020] The term “cancer cells” as referred to as in the present invention means those which are derived from cancer tissues, i.e., cancer cells collected from cancer patients or established cell lines, particularly, cancer cells from tissues of cancer patients to be treated are preferable.

[0021] The methods used for quantifying the expression level of TNF-α-related genes in the present invention are those for determining the expression level of the genes with respect to the expression level of protein, i.e., those for quantifying the expression level of TNF-α-related proteins using cancer cells intact or after extracting the proteins from the cells with appropriate methods; enzyme immunoassay (EIA), radioimmunoassay (RIA), immunoprecipitation, immunocyte staining method, electrophoresis, western blotting, panning method, high-performance liquid chromatography (HPLC), peptide sequencing method, etc., which can be used in an appropriate combination.

[0022] The methods used for determining the expression level of mRNAs of TNF-α-related genes in the present invention are those for quantifying the mRNAs expressed in cancer cells by using the cells intact or by extracting the mRNAs from the cells, or quantifying the level of cDNAs synthesized by reverse transcriptase using the mRNAs as templates; conventional Northern blot technique, Southern blot technique, hybridization method, magnetic bead technology, electrophoresis, polymerase chain reaction (PCR) method, and DNA sequencing method, etc., which can be used in an appropriate combination. In the present invention, the later described real time PCR method as a modified method of PCR method is most preferably used because of its superior processing speed and quantifying accuracy. Without the need of extracting from cancer cells, the mRNAs or their corresponding cDNAs usable in the present invention can be obtainable by appropriately selecting them from RNAs or their corresponding cDNAs, which are derived from commercially available cells, organs, or tissues; as well as their processed products in the form of a pre-blotting membrane or DNA microarray technology.

[0023] Explaining the methods used for examining the sensitivity of cancer cells to TNF-α in the present invention, either cancer cells collected from patients suffering from cancers such as intestinal cancer, lung cancer, pancreatic cancer, breast cancer, gastric cancer, hepatoma, renal cancer, neural cancer, skin cancer, cancer of pharynx, sarcoma, and carcinoma uteri; or established cell lines derived from the above cancer cells are cultured in conventional nutrient culture media, supplemented with 0.1 to 10 μg/ml of TNF-α, and incubated for a prescribed period of time, followed by collecting and staining the resulting cells with a dye such as propidium iodide to count death cells or apoptosed cells by a spectrophotometer, flow cytometry, etc. The sensitivity of cells to TNF-α can be determined by comparing the number of death cells or apoptosed cells in the above test cultures with that for a control culture, cultured similarly as in the test cultures but with no addition of TNF-α. Also the sensitivity of cells to TNF-α can be determined by transplanting cancer cells, collected from a cancer patient, to experimental animals such as nude mice, breeding the animals while administering TNF-α and measuring and evaluating the size of the grown tumor masses in the animals.

[0024] The methods used for evaluating the expression level of TNF-α-related genes in the present invention include those which calculate the relative expression level of TNF-α-related genes in patients to be administered with TNF-α based on the expression level of genes, as an internal standard, whose expression levels between cells and tissues are not so different, such as glycolytic pathway enzymes such as glyceraldehyde-3-phosphate dehydrogenase or cytoskeleton proteins such as β-actin; those which calculate an increased or decreased level of TNF-α-related genes in patients to be administered with TNF-α based on the expression level of TNF-α-related genes in normal cells of the same patient's tissue as the cancer cells tested. The data on the expression levels thus obtained should preferably be examined whether there exist the desired significant differences under a prescribed level of significant difference by means of Mann-Whitney U test, Student's Welch's t-test, cluster analysis, etc.

[0025] The following experiments explain the present invention in detail:

Experiment 1

[0026] Sensitivity of Cell Lines, Derived from Different Organs to TNF-α

[0027] Twenty-one different types of cancer cells collected from patients suffering from cancers and 69 different types of established cell lines obtained from American Type Culture Collection (ATCC), Manassas, USA; Japanese Collection of Research Bioresources (JCRB), Tokyo, Japan; European Collection of Cell Cultures (ECACC), North Carolina, USA; German Collection of Microorganisms and Cell Cultures (DSMZ), Braunschweig, Germany; National Institute of Health and Nutrition (NIHN), Tokyo, Japan; and Institute of Development, Aging, and Cancer (IDAC), Miyagi, Japan, were respectively inoculated into an RPMI 1640 medium supplemented with 10% (v/v) fetal calf serum at a cell density of 1×104 cells/ml to 3×104 cells/ml, cultured for a prescribed period of time, admixed with 5 ng/ml of TNF-α, and incubated at 37° C. for 48 hours under 5% (v/v) CO2 atmospheric conditions. As negative controls, cell culture systems free of TNF-α for each type of cells were provided and cultured similarly as above. After culturing, the cells were collected from the resulting cultures and allowed to stand in a cold 70% (v/v) aqueous ethanol solution for two hours to immobilize the cells. The immobilized cells were stained by keeping in a phosphate-buffered saline (pH 7.2) containing 40 μg/ml of propidium iodide for 20 min. The DNA level in each type of cells was measured on “EPICS XL”, a flow cytometry commercialized by Beckman Coulter Inc., CA, USA, and the percentage (%) of apoptosed cells was analyzed on “WINCYCLE”, a prescribed software commercialized by Beckman Coulter Inc., CA, USA. The percentages (%) of apoptosed cells for each type of cells treated with TNF-α were minused those which corresponded to negative controls with no TNF-α, and the obtained data were graded into four ranks: A rank which means that it had a percentage (%) of less than 5%; B rank, a percentage (%) of more than 5% but less than 10%; C rank, a percentage (%) of more than 10% but less than 20%; and D rank, a percentage (%) of more than 20%. The results are in Tables 1 and 2.

	TABLE 1
	Cancer cell	Percentage (%)
			Code		of apoptosed
No.	Origin	Name	No.	Obtention	cells	Rank
1	Intestinal	From colon cancer patient A	3.7	A
	cancer
2	Intestinal	LoVo	CCL229	ATCC	0.1	A
	cancer
3	Intestinal	HCT-15	CCL225	ATCC	28.4	D
	cancer
4	Intestinal	WiDr	CCL218	ATCC	5.4	B
	cancer
5	Intestinal	LS174T	CCL188	ATCC	7.5	B
	cancer
6	Intestinal	CoLo 205	CCL222	ATCC	29.3	D
	cancer
7	Intestinal	HT-29	HTB38	ATCC	1.6	A
	cancer
8	Intestinal	CoLo 678	ACC194	DSMZ	0.3	A
	cancer
9	Intestinal	SW 1116	CCL233	ATCC	23.8	D
	cancer
10	Intestinal	SW 480	CCL228	ATCC	5.8	B
	cancer
11	Intestinal	CoLo 206	ACC21	DSMZ	10.7	C
	cancer
12	Intestinal	DLD-1	CCL221	ATCC	1.4	A
	cancer
13	Lung	From lung cancer patient A	5.0	B
	cancer
14	Lung	From lung cancer patient B	21.2	D
	cancer
15	Lung	From lung cancer patient C	5.4	B
	cancer
16	Lung	From lung cancer patient D	0.2	A
	cancer
17	Lung	From lung cancer patient E	0.3	A
	cancer
18	Lung	From lung cancer patient F	6.3	B
	cancer
19	Lung	EBC-1	JCRB0820	JCRB	18.6	C
	cancer
20	Lung	MRC-5	CCL171	ATCC	1.2	A
	cancer
21	Lung	CALU6	HTB56	ATCC	1.9	A
	cancer
22	Lung	WI-38VA13	CCL75.1	ATCC	8.3	B
	cancer
23	Lung	OBA-LK-1	TKG0572	IDAC	22.2	D
	cancer
24	Lung	CALU3	HTB55	ATCC	1.7	A
	cancer
25	Lung	A 549	CCL185	ATCC	0.1	A
	cancer
26	Lung	CoLo 699	ACC196	DSMZ	0.8	A
	cancer
27	Lung	LU 65	JCRB0079	JCRB	3.0	A
	cancer
28	Pancreatic	PK-1	TKG0239	IDAC	6.2	C
	cancer
29	Pancreatic	PK-9	TKG0240	IDAC	4.0	A
	cancer
30	Pancreatic	KLM-1	TKG0490	IDAC	1.4	A
	cancer
31	Pancreatic	MIA Paca2	CRL1420	ATCC	7.4	B
	cancer
32	Pancreatic	PANC-1	CRL1469	ATCC	7.6	B
	cancer
33	Pancreatic	PK-59	TKG0492	IDAC	3.0	A
	cancer
34	Pancreatic	PK-8	TKG0383	IDAC	9.6	B
	cancer
35	Pancreatic	PK-45H	TKG0493	IDAC	0.6	A
	cancer
36	Breast	ZR-75-1	CRL1500	ATCC	23.4	D
	cancer
37	Breast	YMB-1-E	JCRB0825	JCRB	39.4	D
	cancer
38	Breast	MCF-7	HTB22	ATCC	9.5	B
	cancer
39	Gastric	From gastric cancer patient A	2.8	A
	cancer
40	Gastric	MKN-7	TKG0228	IDAC	0.6	A
	cancer
41	Gastric	MKN-74	JCRB0255	JCRB	0.7	A
	cancer
42	Gastric	MKN-45	JCRB0254	JCRB	7.4	B
	cancer
43	Gastric	MKN-1	JCRB0252	JCRB	2.3	A
	cancer
44	Gastric	MKN-28	JCRB0253	JCRB	1.5	A
	cancer
45	Gastric	AZ 521	JCRB0061	JCRB	0.2	A
	cancer
46	Gastric	SCH	JCRB0251	JCRB	30.5	D
	cancer
47	Hepatoma	From hepatoma patient A	0.2	A
48	Hepatoma	From hepatoma patient B	2.0	A
49	Hepatoma	From hepatoma patient C	10.7	C
50	Hepatoma	From hepatoma patient D	0.1	A
51	Hepatoma	From hepatoma patient E	13.4	C
52	Hepatoma	From hepatoma patient F	0.1	A
53	Hepatoma	HuH28	JCRB0426	JCRB	0.9	A
54	Hepatoma	HuCCT1	JCRB0425	JCRB	0.1	A
55	Hepatoma	HuL-1		NIHN	5.8	B
56	Hepatoma	HepG2	HB8065	ATCC	2.9	A
57	Hepatoma	PLC/PRF/5	CRL8024	ATCC	0.1	A
58	Hepatoma	Li-7	TKG0368	IDAC	3.6	A
59	Hepatoma	HuH7	JCRB0403	JCRB	1.1	A
60	Hepatoma	Hep 3B	HB8064	ATCC	3.6	A
61	Renal	From renal cancer patient A	3.5	A
	cancer
62	Renal	From renal cancer patient B	0.2	A
	cancer
63	Renal	From renal cancer patient C	5.3	B
	cancer
64	Renal	From renal cancer patient D	0.1	A
	cancer
65	Renal cancer	ACHN	CRL1611	ATCC	0.6	A
66	Renal cancer	VMRC-RCW	TKG0447	IDAC	0.1	A
67	Renal cancer	Caki-1	HTB46	ATCC	0.2	A
68	Neurologic	From neurologic cancer	0.2	A
	cancer	cancer patient A
69	Neurologic	U251	JRCB0461	JCRB	1.0	A
	cancer
70	Neurologic	U373 MG	89081403	ECACC	1.2	A
	cancer
71	Neurologic	SCCH-26	JCRB0106	JCRB	2.7	A
	cancer
72	Neurologic	TN-2	TKG0278	IDAC	1.8	A
	cancer
73	Neurologic	HEPM	CRL1486	ATCC	0.1	A
	cancer
74	Neurologic	KINGS-1	IF050435	JCRB	6.3	B
	cancer
75	Skin cancer	From skin cancer patient A	12.0	C
76	Skin cancer	From skin cancer patient B	4.2	A
77	Skin cancer	RPMI 7932	94072246	ECACC	0.1	A
78	Skin cancer	G-361	CRL1424	ATCC	0.1	A
79	Skin cancer	A375	CRL1619	ATCC	2.8	A
80	Skin cancer	SK-MEL-28	HTB72	ATCC	5.9	B
81	Throat	Detroit	CCL138	ATCC	8.8	B
	cancer	562
82	Throat	HO-1-u-1	JCRB0828	JCRB	0.4	A
	cancer
83	Throat	HO-1-N-1	JCRB0831	JCRB	3.2	A
	cancer
84	Throat	FADu	HTB43	ATCC	0.1	A
	cancer
85	Sarcoma	RD	CCL136	ATCC	22.5	D
86	Sarcoma	Hu-09N2	JCRB0428	JCRB	11.6	C
87	Sarcoma	Saos-2	HTB85	ATCC	1.3	A
88	Carcinoma	Ca Ski	CRL1550	ATCC	12.1	C
	uteri
89	Carcinoma	ME-180	HTB33	ATCC	3.0	A
	uteri
90	—	KB	CCL171	ATCC	4.7	A

[0028] As shown in Tables 1 and 2, 56, 18, 7 and 9 out of 90 different types of cells tested were respectively graded into the ranks A to D.

Experiment 2

[0029] Expression of Factors in Cells

[0030] Using “RNEASY MIDI KIT”, an RNA kit commercialized by Qiagen GmbH, Hilden, Germany, RNAs were respectively prepared in usual manner from the 90 different types of cells in Tables 1 and 2. One microgram of each of the RNAs was reacted with 100 μl of a reaction mixture containing one microgram of a separately prepared random hexamer and 100 units of a murine breast viral reverse transcriptase sequentially at 25° C. for 10 min, at 42° C. for 30 min, and 99° C. for 5 min, and then the reaction was suspended to obtain a cDNA.

[0031] Primers for PCR in SEQ ID NOs: 1 to 100, which corresponded to 49 different types of TNF-α-related genes, registered at Unigene, a DNA database; and to a β-actin gene as an internal standard gene, were prepared and in usual manner subjected to real time PCR using “ABIPRISM 7700 SEQUENCE DETECTION SYSTEM”, an apparatus for PCR commercialized by Applied Biosystems Japan, Ltd., Tokyo, Japan: Twenty nanograms of a cDNA, 100 nM of a sense primer, and 100 nM of an antisense primer were dissolved in water to obtain a 12.5 μl aqueous solution which was then admixed with 12.5 μl of “SYBR GREEN PCR MASTERMIX” commercialized by Applied Biosystems Japan, Inc., Tokyo, Japan, to obtain a reaction mixture. Then, the reaction mixture was subjected to 45 cycles of PCR with sequential incubations at 90° C. for 15 sec and at 60° C. for one min, followed by comparing the expression levels for each gene with that of the internal β-actin gene to express the levels in a numerical manner as their relative expression levels. According to the grading of the ranks in Experiment 1, the ranks B, C and D against the rank A in each gene were examined according to Mann-Whitney U test, and the results were evaluated whether they had a significant difference at p<0.01 or p<0.05. The results are in Table 3.

	TABLE 3
	Group
No.	Gene	B	C	D
1	TNF-R55	+	−	−
2	TNF-R75	−	−	−
3	TIMP2	−	−	−
4	SODD	−	−	−
5	TACE	−	−	−
6	TNF-α	−	−	−
7	TRAF1	+	+	−
8	TRAF2	−	−	−
9	FAN	−	−	−
10	Caspase-8	−	−	−
11	Caspase-3	−	−	−
12	Caspase-9	−	−	−
13	HIAP1	−	−	−
14	HIAP2	−	−	−
15	Akt-1	+	+	++
16	Bcl-1	−	−	−
17	Bcl-xL	−	−	−
18	BAD	−	−	−
19	Bax	−	−	−
20	p53	−	−	+
21	Mn-SOD	−	−	−
22	IKK1	−	−	−
23	DR3	+	+	+
24	PKC-β1	−	−	−
25	NF-kBp50	−	−	−
26	NF-kBp65	−	−	−
27	N-SMase	−	−	−
28	ERK1	−	−	−
29	ERK2	−	−	−
30	p38	−	−	−
31	CyclinG1	−	−	−
32	apoptosis	−	−	−
	inhibitor 4
33	cdc25b	−	−	−
34	CyclinD1	−	−	−
35	JAB	−	−	−
36	PKR	−	−	−
37	2,5-OA	−	−	−
38	MDR1	−	−	−
39	MDR3	−	−
40	MRP1	−	−	−
41	MRP2	−	−	−
42	MRP3	−	−	−
43	MRP4	−	−	−
44	MRP5	+	+	+
45	MRP6	−	+	++
46	BCRP	−	−	−
47	COX-2	−	−	−
48	iNOS	−	−	−
49	TGF-β	−	−	−
− : It had no significant difference compared with the group A.
+ : It had a significant difference (p < 0.05) compared with the group A.
++ : It had a significant difference (p < 0.01) compared with the group A.

[0032] As evident from Table 3, the expression levels of Akt-1, DR3, MRP5 and MRP6 genes with respect to the mRNA levels in the cells with a relatively high sensitivity to TNF-α showed a statistically significantly high expression level. FIGS. 1 to 4 show the results of statistical works of all the above expression levels. As shown in FIG. 5, the data on the expression level of Akt-1 gene with respect to the mRNA level in respective established cell lines from intestinal, breast, lung, and pancreatic organs revealed that the cell lines had a higher expression level of Akt-1 gene, resulting in an estimation that the cancers in such organs would have a high potential of being cured by TNF-α.

Experiment 3

[0033] Cluster Analysis

[0034] Based on the profiles of the 49 different types of genes as the results in Experiment 2, the cluster analysis between the genes was conducted by conventional analysis for factors and main ingredients using “EPCLUST”, a commercially available computer software of European Bioinfomatics Institute, Cambridge, UK. The results are in FIG. 6, revealing that Akt-1, MRP5 and MRP6 genes can be classified into the same cluster which exhibits substantially the same dynamics. The data indicates that there exist at least two representative groups of Akt-1 and DR3 genes as gene groups which enable the estimation of therapeutic efficacy of TNF-α.

Experiment 4

[0035] Expression of Cell Membrane Antigen

[0036] In addition to the action of inducing cells to death through the induction of apoptosis, TNF-α has also the action of promoting the expression of ICAM-1 as a cell membrane antigen. It was examined whether there exists any correlation between the expressions of Akt-1 gene and ICAM-1: With reference to the results in Experiment 1, seven types of TNF-α sensitive cells, i.e., those from the lung cancer patient B, HCT-15 cells, RD cells, OBA-LK-1 cells, CoLo 205 cells, CoLo 206 cells, a YMB-1-E cells; and seven types of non-TNF-α-sensitive cells, i.e., those from the colon cancer patient A, the skin cancer patient A, the lung cancer patient E, the neurologic cancer patient A, the hepatoma patient D, PK-45H cells, and MKN-7 cells were selected, and each of which was suspended in an RPMI 1640 medium supplemented with 10% (v/v) of fetal calf serum to give a cell density of 2×104 cells/ml. To three milliliters of each of the resulting cell suspensions, placed in a commercialized 6-well-plate, was added 5 ng/ml of a human TNF-α preparation, and the cell suspensions were incubated at 37° C. for 24 hours under 5% CO2 atmospheric conditions. After culturing, the cells were collected from each culture, and then successively treated with “BBA-3”, a murine anti-human ICAM-1 antibody, commercialized by R & D Systems Inc., Minneapolis, USA, at 4° C. for 40 min, successively washed with a phosphate buffered saline containing 1% (v/v) of calf serum albumin, a fluorescein-labelled anti-mouse immunoglobulin G antibody at 4° C. for 40 min, and 3% (v/v) formalin. The resulting cells were measured for fluorescent intensity on “EPICS XL”, a flow cytometry commercialized by Beckman Coulter Inc., CA, USA, to examine the expression level of ICAM-1 on the surface of cell membranes. The relationship between the data from the flow cytometry and the expression data of Akt-1 gene in Experiment 2 was studied. The results are in FIG. 7. In FIG. 7, the symbols “▾” and “∘” mean TNF-α-sensitive cells and non-TNF-α-sensitive cells, respectively.

[0037] As found in FIG. 7, two out of the seven different types of TNF-α-sensitive cells (“▾”) increased in the expression level of ICAM-1 but the resting five types of cells did not show any change in the expression level, while two out of the seven different types of non-TNF-α-sensitive cells (“∘”) did not exhibit any change in the expression level of ICAM-1 but the resting five types of cells increased in the expression level, and this gave no statistically significant relationship between the TNF-α sensitivity and the expression level of ICAM-1. The TNF-α-sensitive cells “▾” was significantly high in the expression level of Akt-1 gene with respect to its corresponding mRNA level, and there was found a relatively high correlation between the TNF-α-sensitivity and the expression level of Akt-1 gene when examined on Mann-Whitney U test. These results show that the estimation of the therapeutic efficacy of TNF-α by examining the expression level of Akt-1 gene is more preferable in estimating the antitumor effect of TNF-α through the induction of apoptosis than by estimating the expression level of Akt-1 gene as one of the various functions and effects of TNF-α.

[0038] The following example explain the present invention in detail, but should not limit the present invention:

EXAMPLE

[0039] Cancer cells, extracted from five patients suffering from lung cancer, were treated in usual manner to collect RNAs. Using the RNAs as templates, their corresponding cDNAs were prepared with a murine breast viral reverse transcriptase. A reaction mixture was prepared by adding to 20 μg of each of the cDNAs as templates 12.5 μg of “SYBR GREEN PCR MASTERMIX” containing a thermostable DNA polymerase etc., commercialized by Applied Biosystems Japan, Inc., Tokyo, Japan, and either 100 nM of primers for detection of Akt-1 mRNA having nucleotide sequences of SEQ ID NOs:29 and 30, or 100 nM of primers for detection of β-actin mRNA having nucleotide sequences of SEQ ID NOs:99 and 100. The resulting reaction mixtures were subjected to 45 cycles of PCR sequentially at 90° C. for 15 sec and at 60° C. for one minute using “ABIPRISM 7700 SEQUENCE DETECTION SYSTEM”, a real time PCR apparatus. With reference to the expression level of β-actin mRNA as an internal standard, the expression level of Akt-1 gene was calculated.

[0040] The cells from each of the above five patients suffering from lung cancer were intraperitoneally transplanted to 10 nude mice at a cell density of 1×104 cells/head. On two days after the transplantation, five nude mice out of the 10 mice were intravenously administered with 5 ng/head of TNF-α. On three days after the administration, the tumor masses in the mice were measured according to the method disclosed by K. Nakahara in “International Journal of Medicine”, Vol. 34, pp. 263-267 (1984) and compared with those of control nude mice with no administration of TNF-α to evaluate the antitumor effect of TNF-α. As a result, the more the expression level of Akt-1 gene with respect to mRNA level the higher the antitumor effect of TNF-α.

[0041] As described above, according to the present invention, the therapeutic efficacy of TNF-α on cancer cells will be estimated by measuring the expression level of genes such as of Akt-1, DR3, etc., because the sensitivity of TNF-α on cancer cells highly correlates with the expression level of such genes. Thus, the application of the present invention to patients prior to the administration of TNF-α, the desired therapeutic efficacy of TNF-α will be estimated in a safe and sure manner. The measurement of the expression level of Akt-1 gene is suitable for estimating the antitumor effect of TNF-α among the actions and functions of TNF-α. Thus, the present invention enables the screening of the possibility of pharmaceutical uses of TNF-α which the uses had been deemed actually impossible. In addition, the present invention can be applied to examination of the types of cancers treatable with antitumor agents such as TNF-α.

[0042] While there has been described what is at present considered to be the preferred embodiments of the invention, it will be understood the various modifications may be made therein, and it is intended to cover in the appended claims all such modifications as fall within the true spirits and scope of the invention.

Claims

1. A method for estimating the therapeutic efficacy of tumor necrosis factor, comprising a step of evaluating the expression level of a tumor necrosis factor-related gene in a cancer cell.

2. The method of claim 1, wherein said tumor necrosis factor-related gene is one or more genes selected from the group consisting of a protein kinase B (Akt-1) gene, death receptor (DR3) gene, multidrug resistance-associated protein (MRP5) gene, and multidrug resistance-associated protein (MRP6) gene.

3. The method of claim 1, wherein said cancer cell is an established cell or a cancer cell derived from a cancer patient.

4. A kit for estimating the therapeutic efficacy of tumor necrosis factor used in the treatment of cancers, which comprises a thermostable DNA polymerase and an oligonucleotide primer comprising a DNA sequence encoding a gene selected from the group consisitng of a protein kinase B (Akt-1) gene, death receptor (DR3) gene, multidrug resistance-associated protein (MRP5) gene, and multidrug resistance-associated protein (MRP6) gene.